Starlyng-1: A new clinical trial for schizophrenia

The Starlyng-1 study is researching a once-weekly oral capsule in adults with schizophrenia or schizoaffective disorder, that could reduce the burden of daily dosing and lower the possibility of symptoms returning when daily doses are missed.

Understanding schizophrenia & schizoaffective disorder

Schizophrenia is a serious mental health condition that affects how a person thinks, feels and behaves. A stable and fulfilling life for someone living with schizophrenia is possible with the correct treatment and support.

Once-weekly oral medicines

Research has shown that ~90% of patients and caregivers prefer oral pills over any other drug delivery method including injectables,1 but the burden of having to remember to take daily medication is a heavy one. Taking medication as prescribed is important because continuous use of antipsychotic medications reduces the risk of relapse by approximately 70%.2

The Starlyng-1 study is researching a once-weekly oral antipsychotic medication to reduce the burden of daily pills and lower the risk of relapse.

1 Patient Unmet Needs Survey (Q3’21; n=1645 patients and caregivers)
2 Lindenmayer, J. P., Liu-Seifert, H., Kulkarni, P. M., Kinon, B. J., Stauffer, V., Edwards, S. E., Chen, L., Adams, D. H., Ascher-Svanum, H., Buckley, P. F., Citrome, L., & Volavka, J. (2009). Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response. The Journal of Clinical Psychiatry, 70(7), 990–996.